Company Overview
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
The Company is also developing its personalized CAR T platform technology, XCARTâ„¢, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.
Recent News
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Stock Overview
02/01/2023 04:00 PM EST
Investor Relations
JTC Team, LLC.
Jenene Thomas
T: 833-475-8247
xbio@jtcir.com